Director of Nuclear Cardiology and Cardiac PET/CT

Cleveland Clinic Abu Dhabi

Imaging Institute, Nuclear Medicine Swing Wing, 8th Floor

Al Maryah Island, Abu Dhabi, U.A.E.

Phone: +971 55 954 6166

Email: [email protected]

Career Highlights

• Successfully established Nuclear Cardiology and Nuclear Medicine programs at Cleveland Clinic Abu Dhabi in 2014, serving as Director of Nuclear Cardiology and Cardiac PET/CT
• Generated and performed 98% of Nuclear Cardiology patient volume within the Imaging Institute
• Pioneered the establishment of the first Cardiac PET program in the region in 2016, one of selected sites worldwide offering N13-Ammonia PET myocardial perfusion imaging
• Developed a track record of nearly 1500 PET MPI cases including post-processing and interpretation
• Introduced the first and only Cardiac PET Inflammation imaging service in the region
• Established SPECT/CT imaging technique for Cardiac Amyloidosis since 2018, markedly increasing specificity
• Dual board certified by American Board of Nuclear Medicine and Certification Board of Nuclear Cardiology with over 25 years of practice experience
• Prior to Cleveland Clinic Abu Dhabi, established Cardiocheck, the world's first Joint Commission International (JCI) accredited imaging center
• Performed and interpreted more than 50,000 Myocardial Perfusion Imaging (MPI) studies

Education

Fellow in Nuclear Medicine

Rush Presbyterian St. Luke's Medical Center, Chicago, IL

1997 - 1998

Resident in Nuclear Medicine

Rush Presbyterian St. Luke's Medical Center, Chicago, IL

1995 - 1997

Ph.D. Program - Molecular Biology and Genetics

Carnegie Mellon University, Pittsburgh, PA

1994 - 1995

Resident in Diagnostic Radiology

Hacettepe University Faculty of Medicine, Ankara, Turkey

1990 - 1994

Doctor of Medicine

Hacettepe University Faculty of Medicine, Ankara, Turkey

1982 - 1988

Work Experience

Director of Nuclear Cardiology and Cardiac PET/CT, Staff Physician

Cleveland Clinic Abu Dhabi, U.A.E.

2014 - Present

Imaging Institute, Nuclear Medicine and Nuclear Cardiology

Founder and Director

MPIAccureads, TeleNuclearMedicine Inc., Elmhurst, IL, U.S.A.

2012 - 2014

Founder, Manager and Clinical Director

CardioCheck Nuclear Imaging, Ankara, Turkey

1998 - 2011

Licenses / Boards / Certifications

USA License: Illinois, Active No: 036108226

American Board of Nuclear Medicine: No: 06355 (Distinguished Physician)

Certification Board of Nuclear Cardiology: No: 0907

Turkish Board of Nuclear Medicine: No: 49965 47150

Doctor of Medicine: No: 88AA141

Department of Health Authority, Abu Dhabi: No: GD18667

Selected Publications

Recent Publications:

• Alibazoglu H, Khalil AM, Alibazoglu D, et al. Unraveling septal perfusion abnormalities in Ebstein's anomaly: A case report contrasting PET MPI with myocardial reality. Radiol Case Rep. 2025 May 22;20(8):3970-3976.
• Al Taha, Z., Alibazoglu, D., Sabbour, H. et al. Attacking the Achilles heel of cardiac amyloid nuclear scintigraphy: How to reduce equivocal and false positive studies. J. Nucl. Cardiol. (2023).
• Sabbour H, Al-Humood K, Al Taha Z, Romany I, Haddadin H and Mohty D. A wolf in sheep's clothing---aortic stenosis and cardiac amyloidosis: "RAISE"ing awareness in clinical practice. Front Cardiovasc Med. 11:1323023 (2024).
• Khalil M, Alibazoglu D, Balci CN, Hussein R, Abuwadi A, Alibazoglu H. Discordance between invasive coronary flow reserve(CFR) and non-invasive myocardial flow reserve(MFR) in diffuse coronary ectasia(DCE). BJR Case Rep. 2020 Sep;6(2):20190046.

Early Career Publications:

• Patel PM, Alibazoglu H, Ali A, et al: Normal thymic uptake of FDG on PET imaging. Clin Nucl Med. 1996 Oct;21(10):772-775.
• Nair N, Ali A, Green AA, Alibazoglu H, et al: Response of osteosarcoma to chemotherapy: Evaluation with F-18 FDG-PET. Clinical Positron Imaging. 2000 Mar;3(2):79-83.